CN1425763A - Use of icariin in inducing external oriented differentiation of embryo stem cells - Google Patents
Use of icariin in inducing external oriented differentiation of embryo stem cells Download PDFInfo
- Publication number
- CN1425763A CN1425763A CN02160367A CN02160367A CN1425763A CN 1425763 A CN1425763 A CN 1425763A CN 02160367 A CN02160367 A CN 02160367A CN 02160367 A CN02160367 A CN 02160367A CN 1425763 A CN1425763 A CN 1425763A
- Authority
- CN
- China
- Prior art keywords
- cell
- icarin
- stem cell
- embryo stem
- icariin
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- TZJALUIVHRYQQB-UHFFFAOYSA-N icariine Natural products C1=CC(OC)=CC=C1C1=C(OC2C(C(O)C(O)C(C)O2)O)C(=O)C2=C(O)C=C(OC3C(C(O)C(O)C(CO)O3)O)C(CC=C(C)C)=C2O1 TZJALUIVHRYQQB-UHFFFAOYSA-N 0.000 title claims abstract description 62
- 230000004069 differentiation Effects 0.000 title claims abstract description 30
- 230000001939 inductive effect Effects 0.000 title claims abstract description 27
- 210000000130 stem cell Anatomy 0.000 title claims abstract description 25
- 210000001161 mammalian embryo Anatomy 0.000 title claims abstract description 24
- TZJALUIVHRYQQB-XLRXWWTNSA-N icariin Chemical compound C1=CC(OC)=CC=C1C1=C(O[C@H]2[C@@H]([C@H](O)[C@@H](O)[C@H](C)O2)O)C(=O)C2=C(O)C=C(O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O3)O)C(CC=C(C)C)=C2O1 TZJALUIVHRYQQB-XLRXWWTNSA-N 0.000 title abstract description 9
- TZJALUIVHRYQQB-XFDQAQKOSA-N Icariin Natural products O(C)c1ccc(C2=C(O[C@H]3[C@@H](O)[C@H](O)[C@@H](O)[C@H](C)O3)C(=O)c3c(O)cc(O[C@H]4[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O4)c(C/C=C(\C)/C)c3O2)cc1 TZJALUIVHRYQQB-XFDQAQKOSA-N 0.000 title abstract description 6
- 210000004027 cell Anatomy 0.000 claims abstract description 77
- 239000003814 drug Substances 0.000 claims abstract description 21
- 230000000694 effects Effects 0.000 claims abstract description 13
- 210000004165 myocardium Anatomy 0.000 claims abstract description 12
- 238000012216 screening Methods 0.000 claims abstract description 9
- 230000002107 myocardial effect Effects 0.000 claims description 21
- 238000000338 in vitro Methods 0.000 claims description 12
- 239000003795 chemical substances by application Substances 0.000 claims description 8
- 230000008929 regeneration Effects 0.000 claims description 5
- 238000011069 regeneration method Methods 0.000 claims description 5
- 238000011476 stem cell transplantation Methods 0.000 claims description 5
- 210000003725 endotheliocyte Anatomy 0.000 claims description 3
- 238000011156 evaluation Methods 0.000 claims description 3
- 239000000178 monomer Substances 0.000 claims description 3
- 210000002064 heart cell Anatomy 0.000 claims 1
- 230000000144 pharmacologic effect Effects 0.000 abstract description 3
- 238000013459 approach Methods 0.000 abstract description 2
- 230000007246 mechanism Effects 0.000 abstract description 2
- 230000009756 muscle regeneration Effects 0.000 abstract description 2
- 230000002265 prevention Effects 0.000 abstract description 2
- 230000003285 pharmacodynamic effect Effects 0.000 abstract 2
- 210000004413 cardiac myocyte Anatomy 0.000 abstract 1
- 230000018109 developmental process Effects 0.000 abstract 1
- 239000003226 mitogen Substances 0.000 abstract 1
- 238000011160 research Methods 0.000 description 11
- 210000002242 embryoid body Anatomy 0.000 description 9
- 210000001671 embryonic stem cell Anatomy 0.000 description 9
- 230000000857 drug effect Effects 0.000 description 8
- 238000000034 method Methods 0.000 description 7
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 5
- 244000309466 calf Species 0.000 description 5
- 238000002474 experimental method Methods 0.000 description 5
- 210000002966 serum Anatomy 0.000 description 5
- 241000893536 Epimedium Species 0.000 description 4
- 230000009471 action Effects 0.000 description 4
- 235000018905 epimedium Nutrition 0.000 description 4
- 230000008569 process Effects 0.000 description 4
- 229930182470 glycoside Natural products 0.000 description 3
- 230000006698 induction Effects 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 235000015097 nutrients Nutrition 0.000 description 3
- 241000196324 Embryophyta Species 0.000 description 2
- 238000004115 adherent culture Methods 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 210000001112 cardioblast Anatomy 0.000 description 2
- 230000003915 cell function Effects 0.000 description 2
- 239000006285 cell suspension Substances 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 239000003636 conditioned culture medium Substances 0.000 description 2
- 239000000470 constituent Substances 0.000 description 2
- 238000007796 conventional method Methods 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 239000000284 extract Substances 0.000 description 2
- 150000002338 glycosides Chemical class 0.000 description 2
- 210000004409 osteocyte Anatomy 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 238000004114 suspension culture Methods 0.000 description 2
- 230000001550 time effect Effects 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 208000036762 Acute promyelocytic leukaemia Diseases 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- 241000133570 Berberidaceae Species 0.000 description 1
- 206010006458 Bronchitis chronic Diseases 0.000 description 1
- BHPQYMZQTOCNFJ-UHFFFAOYSA-N Calcium cation Chemical compound [Ca+2] BHPQYMZQTOCNFJ-UHFFFAOYSA-N 0.000 description 1
- 241001498094 Epimedium hunanense Species 0.000 description 1
- 241000893531 Epimedium koreanum Species 0.000 description 1
- 241001362411 Epimedium sagittatum Species 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- -1 Flavonol Glycosides Chemical class 0.000 description 1
- 206010019280 Heart failures Diseases 0.000 description 1
- 206010021143 Hypoxia Diseases 0.000 description 1
- 108090000862 Ion Channels Proteins 0.000 description 1
- 102000004310 Ion Channels Human genes 0.000 description 1
- 208000012902 Nervous system disease Diseases 0.000 description 1
- 208000018737 Parkinson disease Diseases 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 208000000474 Poliomyelitis Diseases 0.000 description 1
- 208000033826 Promyelocytic Acute Leukemia Diseases 0.000 description 1
- 101710172711 Structural protein Proteins 0.000 description 1
- 108010017842 Telomerase Proteins 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- SHGAZHPCJJPHSC-YCNIQYBTSA-N all-trans-retinoic acid Chemical compound OC(=O)\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C SHGAZHPCJJPHSC-YCNIQYBTSA-N 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 230000001929 anti-hepatotoxic effect Effects 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 206010006451 bronchitis Diseases 0.000 description 1
- 229910001424 calcium ion Inorganic materials 0.000 description 1
- 230000030833 cell death Effects 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 238000002659 cell therapy Methods 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 208000007451 chronic bronchitis Diseases 0.000 description 1
- 238000003501 co-culture Methods 0.000 description 1
- 208000029078 coronary artery disease Diseases 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 230000001079 digestive effect Effects 0.000 description 1
- 210000002249 digestive system Anatomy 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 238000009509 drug development Methods 0.000 description 1
- 238000007877 drug screening Methods 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 230000002526 effect on cardiovascular system Effects 0.000 description 1
- 230000001856 erectile effect Effects 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 230000000763 evoking effect Effects 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- HVQAJTFOCKOKIN-UHFFFAOYSA-N flavonol Natural products O1C2=CC=CC=C2C(=O)C(O)=C1C1=CC=CC=C1 HVQAJTFOCKOKIN-UHFFFAOYSA-N 0.000 description 1
- 235000011957 flavonols Nutrition 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 235000008216 herbs Nutrition 0.000 description 1
- 230000002519 immonomodulatory effect Effects 0.000 description 1
- 230000005934 immune activation Effects 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 238000012151 immunohistochemical method Methods 0.000 description 1
- 230000001506 immunosuppresive effect Effects 0.000 description 1
- 201000001881 impotence Diseases 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 108040006849 interleukin-2 receptor activity proteins Proteins 0.000 description 1
- 210000004153 islets of langerhan Anatomy 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 230000009191 jumping Effects 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 210000003127 knee Anatomy 0.000 description 1
- 238000002386 leaching Methods 0.000 description 1
- 230000003908 liver function Effects 0.000 description 1
- 210000003810 lymphokine-activated killer cell Anatomy 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 108020004999 messenger RNA Proteins 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 229930014626 natural product Natural products 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 230000001537 neural effect Effects 0.000 description 1
- 210000002241 neurite Anatomy 0.000 description 1
- 208000015122 neurodegenerative disease Diseases 0.000 description 1
- 210000002569 neuron Anatomy 0.000 description 1
- 239000002547 new drug Substances 0.000 description 1
- 230000001582 osteoblastic effect Effects 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 230000010349 pulsation Effects 0.000 description 1
- 238000010298 pulverizing process Methods 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 229930002330 retinoic acid Natural products 0.000 description 1
- 230000001020 rhythmical effect Effects 0.000 description 1
- 230000007480 spreading Effects 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 238000005728 strengthening Methods 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- ZRKFYGHZFMAOKI-QMGMOQQFSA-N tgfbeta Chemical compound C([C@H](NC(=O)[C@H](C(C)C)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CCSC)C(C)C)[C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O)C1=CC=C(O)C=C1 ZRKFYGHZFMAOKI-QMGMOQQFSA-N 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 238000002054 transplantation Methods 0.000 description 1
- 210000004881 tumor cell Anatomy 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 210000003556 vascular endothelial cell Anatomy 0.000 description 1
- 210000004509 vascular smooth muscle cell Anatomy 0.000 description 1
- 230000000304 vasodilatating effect Effects 0.000 description 1
Landscapes
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
The present invention provides a new use icariin in inducing external oriented differentiation of embryo stem cells into single type of cells. Icariin may be used as the mitogen in stem cell transplanting cardiac muscle regeneration or cardiac muscle cell reconstruction, and in constructing high-efficiency pharmacodynamic screening model for initial screening and estimation of medicine effect. The present invention demonstrates the medicine effect of icariin in cell level and approaches its plentiful biological information. The present invention determines icariin as pharmacological active componnet and this provides Chinese medicine prevention and treatment with substantil foundation. At the same time, the description of the pharmacodynamic mechanism provides reference for modernized development of Chinese medicine.
Description
Technical field
The invention belongs to area of pharmacology, the purposes that relates to a kind of traditional Chinese medicine monomer compound, be specifically related to the purposes of icarin aspect the in-vitro directed differentiation of inducing embryo stem cell, can be used for the short cell differential agent in regeneration of stem cell transplantation cardiac muscle or the cell cardiac muscle Reconstruction.
Background technology
Herba Epimedii (Herba Epimedii) has another name called Herba Epimedii, ground drying nest for Berberidaceae (Berberbidaceae) Epimedium (Epimedium) various plants, the effect of have kidney invigorating and YANG supporting, strengthening the muscles and bones, dispelling rheumatism is usually used in treating that impotence erectile problem, urine are dripping, weakness of the waist and knees and diseases such as coronary heart disease, chronic bronchitis, neural decline and poliomyelitis.Modern pharmacological research proves that Herba Epimedii contains special chemical ingredients and significant biological activity, is a kind of medicine with extensive pharmacologically active.
(Epimedium Icariine is to separate the natural product of purifying from Herba Epimedii EI) to icarin, is a monomeric compound, is the effective constituent of Herba Epimedii.Chemical structural formula is:
Its leaching process of R1=-Glc R2=-Rha is roughly gets epimedium herb, pulverizing → extraction using alcohol → the obtain icarin that medicinal extract extract → top condition extracted → obtained higher degree.
Icarin has multiple pharmacologically active, and all there are certain pharmacological action in blood system, immunity system, marrow system:
1. icarin has the effect that suppresses the acute promyelocytic leukemia cell telomerase activation.
2. icariine has antitumor action, and it has tangible propagation and differentiation-inducing action to the HL-60 cell existing experiment confirm, can inducing apoptosis of tumour cell.
3. icarin can be adjusted to ALP activity in the osteocyte, promotes osteoblastic proliferation, is enhanced to the osteocyte activity.
4. icariine has immune activation effect.By recovering LAK cell IL-2R alpha expression, improve CD
3Pore-forming protein mRNA level and promotion CD in the AK cell
3AK propagation reverses TGF β 2 couples of LAK, CD
3The immunosuppressive action of AK.
5. icarin can promote the growth of neurocyte.
6. thereby icarin energy anti-hypoxia pours into and improves liver function.
7. icarin reaches vasodilative effect by suppressing the outer flow of calcium ions of vascular smooth muscle cell.
But have not yet to see the report that icarin is used for the inducing embryo stem cell directed differentiation.
Summary of the invention
An object of the present invention is to provide a kind of new purposes of icarin, is to be divided into multiple single type cell by the icarin inducing embryo stem cell is in-vitro directed, comprises myocardial cell, neurocyte, endotheliocyte etc.
Another object of the present invention is the single type cell that utilizes the in-vitro directed differentiation of icarin energy inducing embryo stem cell to obtain, and can be used for the short cell differential agent in regeneration of stem cell transplantation cardiac muscle or the cell cardiac muscle Reconstruction.
Another purpose of the present invention is the single type cell that utilizes the in-vitro directed differentiation of icarin energy inducing embryo stem cell to obtain, and also can be used for making up the high-level efficiency medicine efficacy screening model, and utilizes this model to carry out medicine effect preliminary screening and evaluation.
The present invention's drug effect to icarin on the cell aspect has been carried out strict demonstration, and the large number of biological information of wherein containing has been carried out preliminary discussion, and following advantage is specifically arranged:
1. the present invention has opened up the new purposes of icarin, and promptly the inducing embryo stem cell directed differentiation is multiple single type cell (myocardial cell, neurocyte, an endotheliocyte etc.).
2. sheep leaves of pulse plants glycosides can be used as the short cell differential agent in stem cell transplantation cardiac muscle regeneration (myocardial regeneration) or the cell cardiac muscle Reconstruction (cellular cardiomyoplasty).The regeneration of stem cell transplantation cardiac muscle is in the experimental study stage (containing clinical and experimental study) at present, and the intervention of the short cell differential agent icarin of expectation will help the research in this field.
3. one aspect of the present invention is clear and definite possesses the composition icarin of pharmacologically active, and for the Chinese herb prevention effect provides material base, the new drug that has an independent intellectual property right for modernization of Chinese medicine exploitation of illustrating of drug effect mechanism is offered reference on the other hand.
Description of drawings
Fig. 1 induces the ES-D3 cell directional for icarin and is divided into myocardial cell's dose-effect relationship figure.
The specific examples mode
The present invention is further described in conjunction with the accompanying drawings and embodiments.Should be understood that in addition following preferred specific embodiments only illustrates, but not limit the scope of the invention by any way.
Embodiment 1: the in-vitro directed research that is divided into the myocardial cell of icarin inducing embryo stem cell (ES cell)
1.ES the support of cell is cultivated:
ES cell D3 cell strain (ES-D3 cell) is in conditioned medium (containing DMEM substratum, foetal calf serum), by 2 * 10
7-5 * 10
7The density of individual/ml is inoculated on trophocyte's (l cell or STO cell strain), the cultivation of going down to posterity according to a conventional method.
2. icarin induces the ES cell directional to be divided into myocardial cell's cultivation:
1. the ES-D3 cell is made single cell suspension with trysinization, is inoculated on the cover inner surface of culture dish by 20-30 μ L, adds 10ml D-Hanks liquid in the culture dish, and the lid upset is formed hanging drop, puts in the incubator hanging drop and cultivates 2 days.After this hanging drop is changed in the culture dish that fills 10ml ES cytodifferentiation substratum (containing DMEM substratum, foetal calf serum), carried out ES cell colony suspension culture 3 days, form ES cell embryoid body.
2. the differentiation culture that adheres to the ES cell: embryoid body is transferred in 24 orifice plates with suction pipe at microscopically, was hatched 4-5 hour, make its absorption after, slowly add 1ml ES division culture medium in every hole, add traditional Chinese medicine monomer icarin and ES cell embryoid body and hatch altogether.Begin this moment with inverted microscope observation of cell every day, begin the initial time of dancing to catch the myocardial cell.
Embodiment 2: the icarin directed differentiation is the purposes of myocardial cell aspect evaluating drug effect
Embryoid body cell mass by embodiment 1 acquisition, if rhythmicity can be arranged beat, then with this index as the directed differentiation cardioblast, make time-effect relationship curve and the amount effect relation curve (referring to Fig. 1) of medicine icarin, with this index as evaluating drug effect to the differentiation of ES-D3 cell induction.Also can be used for the screening of drug development and active ingredient of Chinese herbs.Referring to Fig. 1, icarin induces effect that the ES cell directional is divided into the myocardial cell clearly, and has good dose-effect relationship, and itself and ES-D3 co-culture of cells are in the time of 5-7 days, just there is the cell clone more than 90% rhythmic pulsation to occur, and heart plumule scleroproein up-regulated is arranged.Among Fig. 1, the icarin final concentration is respectively :-▲-0, and-■-10
-8,-◆-10
-7MolL
-1 *P＜0.05,
*P＜0.01
* *P＜0.001vs 0molL
-1, each concentration n=400 embryoid body, identical experiment repeats to have done 6 times.
Utilizing embryonic stem cell (embryonic stem cells, ES cell) directed differentiation to prove icarin for myocardial cell's medicine efficacy screening model is divided into this process of myocardial cell to the ES cell directional and has significant inducing action.In the experiment with the ES cell as the experiment test carrier, with substratum (containing DMEM and foetal calf serum) the ES cell is made single cell suspension, hanging drop cultivate to form embryoid body again, embryoid body carries out adherent culture again; This moment add icarin cultivate altogether (and with the internationally recognized differentiation agent vitamin A acid A that induces as positive control drug, with not dosing group as negative control group), beat with the embryoid body cell mass is the index of directed differentiation cardioblast success with having rhythmicity.Induce the embryoid body cell mass to beat according to icarin, and the time-effect relationship and the dose-effect relationship of this drug-induced differentiation carry out statistical analysis with rhythmicity occurring, with this as the evaluating drug effect index.The result shows that icarin can make the ES cytodifferentiation time significantly shift to an earlier date (P＜0.05), is divided into the myocardial cell and leads and significantly improve (P＜0.05, P＜0.01, P＜0.001) (accompanying drawing 1).And icarin group inductive myocardial cell and its jumping frequency rate of control group comparison and intensity all have increase in the experiment.Icarin has significant induction of differentiation to the ES cytodifferentiation for this process of myocardial cell, and it is the novel differentiation agent of inducing of action target spot with the heart that the medicine icarin is expected to become a kind of.Owing to induce the ES cell directional to be divided into and be rich in myocardial cell's the process at icarin and grow the dependency bioinformation, can provide a lot of target spots to use for evaluating drug effect, the index of therefore cardiac muscle can be grown that the dependency special gene is expressed, myocardial structural protein expression and ionic channel formation etc. can the reflecting myocardium cell functions, by technology such as patch clamp, PCR, immunohistochemical methodss the drug effect of icarin is carried out deep evaluation, to prove the promoter action of icarin to myocardial cell's growth and function improvement.
Embodiment 3: the icarin directed differentiation is myocardial cell's purposes in other respects
Utilize icarin inducing embryo stem cell directed differentiation to be the myocardial cell, as if it successfully being introduced depleted heart and working with host cell, then this approach can become the vital tissue cell source of transplantation treatment cardiac insufficiency; Can cultivate a large amount of myocardial cell clones in this way, other aspect researchs such as organizational engineering are provided.
Embodiment 4: icarin inducing embryo stem cell directed differentiation is the research of neurocyte
Icarin has very strong inducing action to embryonic stem cell, and neurocyte is had the nourishing provide protection.Can select the method for adherent culture, be divided into neurocyte with the icarin inducing embryo stem cell.
1.ES the support of cell is cultivated
ES cell D3 cell strain (ES-D3 cell) is in conditioned medium (containing DMEM substratum, foetal calf serum), by 2 * 10
7-5 * 10
7The density of individual/ml is inoculated on trophocyte's (l cell or STO cell strain), the cultivation of going down to posterity according to a conventional method.
2. icarin inducing embryo stem cell directed differentiation is a neurocyte
Get the ES-D3 cell that is in logarithmic phase, with 0.25% trypsinase-EDTA Digestive system had digestive transfer culture, by 5 * 10
5Cell/ml is inoculated in suspension culture in the Micro-Organism Culture Dish of spreading agar, and nutrient solution changes the DMEM nutrient solution that contains 15% foetal calf serum, no mercaprol and LIF into.Change liquid behind the 2d and continue to cultivate two days formation EB,, EB is broken up, be inoculated in the adhesivity tissue culture flasks and cultivate, add suitable concn icarin (10 this moment by the 5th day
-8-10
-6Mol/L) nutrient solution and ES-D3 cell are hatched altogether, and every 2d changes liquid 1 time, induces it to be divided into neurocyte.
Existing known many nervous system disorderss such as Parkinson's disease be since nerve cell death and ripe neurocyte can't divide replenished caused.Become neurocyte as under the icarin effect, embryonic stem cell being induced, again these Transplanted cellss are gone in the brain, can be used for the cell therapy research of nerve degenerative diseases such as Parkinson and other central nervous systems; Also can be used for the neurocyte is the drug screening and the toxicity assessment of action target spot, makes up the big evaluating drug effect model of reliable bioinformation amount.
Embodiment 5: icarin inducing embryo stem cell directed differentiation is the research of other kind cells
Icarin is hatched altogether with suitable concentration and embryonic stem cell, adopt different cultural methods embryo stem cell for directional can be divided into the other types cell, as islet cells, vascular endothelial cell etc., all can be used for making up medicaments sifting model and transplantability treatment research.
Need not further to elaborate, believe and adopt the disclosed content in front, those skilled in the art can use the present invention to greatest extent.All quote in this application as a reference at all documents that the present invention mentions, just quoted as a reference separately as each piece document.Should be understood that in addition those skilled in the art can make various changes or modifications the present invention after having read above-mentioned teachings of the present invention, these equivalent form of values fall within the application's appended claims institute restricted portion equally.
The partial reference document 1 that the present invention relates to, H.-R.Liang, P.Vuorela, H.Vuorela, R.Hiltunen Isolation and ImmunomodulatoryEffect of Flaconol Glycosides from Epimedium hunanense Planta Medica63 (1997) 316-319.2, Joseph MM, Linda CS, Elizabeth MR, et al.Embryonic stem cell cardiogenesisapplication for cardiovascular research.TCM, 1997,7 (2): 63-68.3, Mi-Kyeong Lee, Young-Joo Choi, Sang-Hyun Sung et al.AntihepatotoxicActivity of Icariin, a Major Constituent of Epimedium Koreanum PlantaMed.61 (1995) 523-526.4, all same merit, old system is ancient, Liu Lanying, Deng. the cultivation of mouse embryo stem cell. Chinese experimental animal journal, 1999,7 (1): 1-4.5, beautiful, Du Guanhua. the medicaments sifting model progress. preclinical medicine and clinical, 2001,21 (4): 302-304.6, Guo Xiaoxia, He Fuchu. the research of embryonic stem cell and utilization. Science Bulletin, 2000,45 (5): 467-474.7, Du Zhongwei, Cong Xiaoqian. the progress of embryonic stem cell vitro differentiation. the cytobiology magazine, 1998,20 (3): 102-106.8, Xue Qing philanthropist compiles. and " philosophy and technique of vitro culture ". the .9 of Science Press, Shen Gan, Cong Xiaoqian, Liu Xiaoyin, Wang Zheng, Cao Yilin. the research of embryonic stem cell neuralward cell induction differentiation. foreign medical science biomedical engineering fascicle, 2002,25 (4): 150-156.10, Ge Jian, Guo Yan, Wang Zhichong, bang spring etc., external evoked embryo stem cell for directional is divided into the preliminary study of neurocyte, dissect journal, 2001,32 (4): 301-305.11, Minpei Kuroda, Yoshihiro Mimaki, Yutaka Sashida, Emiko Umegaki etal.Flavonol Glycosides from Epimedium sagittatum and Their Neurite OutgrowthActivity on PC12h Cells.Planta Med, 2000,66:575-577.
Claims (4)
1. the purposes of an icarin aspect the in-vitro directed differentiation of inducing embryo stem cell, it is characterized in that: be divided into multiple single type cell in-vitro directed with monomer icarin inducing embryo stem cell, this single type cell can be used as short cell differential agent, also can be used for making up the high-level efficiency medicine efficacy screening model.
2. the purposes of icarin according to claim 1 aspect the in-vitro directed differentiation of inducing embryo stem cell, it is characterized in that: icarin is can inducing embryo stem cell in-vitro directed to be divided into multiple single type cell, comprises myocardial cell, neurocyte, endotheliocyte etc.
According to claim 1 and 2 described icarin in the purposes aspect the in-vitro directed differentiation of inducing embryo stem cell, it is characterized in that:, be to be used for regeneration of stem cell transplantation cardiac muscle or cell cardiac muscle Reconstruction as short cell differential agent.
According to claim 1 and 2 described icarin in the purposes aspect the in-vitro directed differentiation of inducing embryo stem cell, it is characterized in that: utilize the high-level efficiency medicine efficacy screening model that makes up, can carry out medicine effect preliminary screening and evaluation.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNB021603677A CN1164741C (en) | 2002-12-30 | 2002-12-30 | Use of icariin in inducing external oriented differentiation of embryo stem cells |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNB021603677A CN1164741C (en) | 2002-12-30 | 2002-12-30 | Use of icariin in inducing external oriented differentiation of embryo stem cells |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN1425763A true CN1425763A (en) | 2003-06-25 |
| CN1164741C CN1164741C (en) | 2004-09-01 |
Family
ID=4753434
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CNB021603677A Expired - Fee Related CN1164741C (en) | 2002-12-30 | 2002-12-30 | Use of icariin in inducing external oriented differentiation of embryo stem cells |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN1164741C (en) |
Cited By (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2008101412A1 (en) * | 2007-02-16 | 2008-08-28 | Xuanwu Hospital Of Capital Medical University | The use of epimedium flavones and effective components thereof for the preparation of medicaments of promoting proliferations and differentiations of nerve cells |
| CN103045536A (en) * | 2011-10-14 | 2013-04-17 | 北京清美联创干细胞科技有限公司 | Establishment and application for embryonic stem cell in vitro differentiation traditional Chinese medicine active substance pharmacodynamic screening model |
| CN103181941A (en) * | 2011-12-31 | 2013-07-03 | 北京东方百奥医药开发有限公司 | Application of icariin or icarisid II in preparation of medicine for preventing and curing diabetic retinopathy |
| CN103439513A (en) * | 2013-08-05 | 2013-12-11 | 浙江大学 | Pharmaceutical application of Rictor/mTORC2 in heart development and disease treatment |
| CN1863904B (en) * | 2003-10-03 | 2014-05-28 | 福田惠一 | Method of inducing the differentiation of stem cells into myocardial cells |
| CN106520690A (en) * | 2016-12-24 | 2017-03-22 | 严志海 | Serum-free stem cell culture medium |
| CN108715829A (en) * | 2018-05-25 | 2018-10-30 | 大连医科大学 | A method of improving Human in vitro Fertilization embryo development rate |
| CN110157663A (en) * | 2019-04-18 | 2019-08-23 | 朗姿赛尔生物科技（广州）有限公司 | A kind of stem cell external evoked method for cultivating cardiac muscle cell |
-
2002
- 2002-12-30 CN CNB021603677A patent/CN1164741C/en not_active Expired - Fee Related
Cited By (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1863904B (en) * | 2003-10-03 | 2014-05-28 | 福田惠一 | Method of inducing the differentiation of stem cells into myocardial cells |
| WO2008101412A1 (en) * | 2007-02-16 | 2008-08-28 | Xuanwu Hospital Of Capital Medical University | The use of epimedium flavones and effective components thereof for the preparation of medicaments of promoting proliferations and differentiations of nerve cells |
| CN103045536A (en) * | 2011-10-14 | 2013-04-17 | 北京清美联创干细胞科技有限公司 | Establishment and application for embryonic stem cell in vitro differentiation traditional Chinese medicine active substance pharmacodynamic screening model |
| CN103181941A (en) * | 2011-12-31 | 2013-07-03 | 北京东方百奥医药开发有限公司 | Application of icariin or icarisid II in preparation of medicine for preventing and curing diabetic retinopathy |
| CN103439513A (en) * | 2013-08-05 | 2013-12-11 | 浙江大学 | Pharmaceutical application of Rictor/mTORC2 in heart development and disease treatment |
| CN103439513B (en) * | 2013-08-05 | 2015-07-29 | 浙江大学 | The pharmaceutical use of Rictor/mTORC2 in heart development and disease treatment |
| CN106520690A (en) * | 2016-12-24 | 2017-03-22 | 严志海 | Serum-free stem cell culture medium |
| CN108715829A (en) * | 2018-05-25 | 2018-10-30 | 大连医科大学 | A method of improving Human in vitro Fertilization embryo development rate |
| CN110157663A (en) * | 2019-04-18 | 2019-08-23 | 朗姿赛尔生物科技（广州）有限公司 | A kind of stem cell external evoked method for cultivating cardiac muscle cell |
| CN110157663B (en) * | 2019-04-18 | 2021-07-27 | 朗姿赛尔生物科技（广州）有限公司 | Method for culturing myocardial cells by stem cell in vitro induction |
Also Published As
| Publication number | Publication date |
|---|---|
| CN1164741C (en) | 2004-09-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP1788079A1 (en) | Animal tissue-eccentrically located pluripotent cell proliferating selectively in low-serium medium | |
| CN103153318B (en) | For the cell culture system of the Bioreactor scaleup of cell | |
| CN102978156A (en) | Expansion in vitro purification culture method of mesenchymal stem cells and culture medium | |
| EP2489727A2 (en) | Method of inducing high activity of human adipose stem cell and medium therefor | |
| CN1164741C (en) | Use of icariin in inducing external oriented differentiation of embryo stem cells | |
| CN109988746A (en) | A kind of mescenchymal stem cell adipogenic induction differentiation method | |
| CN103387959A (en) | Stem cell from deciduous teeth, and preparation method and application thereof | |
| CN101531996B (en) | Method for separating and purifying mesenchymal stem cells originated from formation tissue | |
| CN1778905B (en) | Separating culture and use for fatty mesenchymal dry cell | |
| CN107287156A (en) | A kind of isolated culture method of fat mesenchymal stem cell and its application | |
| CN103215222A (en) | Induction medium for inducing human adipose tissue-derived stromal cells as nerve cells and method | |
| CN1536075A (en) | Method for inducing bone marrow mesenchymal stem cells to differentiate into insulin-like cells | |
| CN116640727B (en) | Nutrient solution for improving cell viability and preparation method and application thereof | |
| KR20070114449A (en) | A method for isolating and culturing mesenchymal stem cell derived from umbilical cord blood | |
| CN102822331A (en) | Method for increasing activity in human stem cell | |
| CN1869204A (en) | Use of icariin in inducting dry cell body in-vitro directional differentiation | |
| CN105112367B (en) | A kind of mescenchymal stem cell epidermal differentiation derivant and its application process | |
| CN105505875A (en) | Culture medium and culture method for efficiently inducing stem cell directional differentiation | |
| KR102097005B1 (en) | A composition for stimulating differentiation of stem cell comprising multi-layer graphene film and culture broth of progenitor cell | |
| Jeong et al. | Effects of inoculum conditions on growth of hairy roots of Panax ginseng CA Meyer | |
| CN1141384C (en) | Human marrow-interstitial stem cell and its preparing process | |
| Mazurkevych et al. | The effect of a fibroblast growth factor, insulin-like growth factor, growth hormone, and Biolaminin 521 LN on the proliferative activity of cat stem cells | |
| CN109628387A (en) | Composition, induction culture solution and abductive approach containing the composition | |
| CN109576215A (en) | A method of induction dental pulp stem cell Cardiocytes differentiation | |
| CN1291011C (en) | In vitro culturing method of oviduct secretory cell of Chinese forest frog |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| C17 | Cessation of patent right | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20040901 Termination date: 20131230 |